Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Alternative disease management in Crohn's disease

Alternative strategies reduce the total cost of care for steroid treated chronically active Crohn's patients, reports October's American Journal of Gastroenterology.

News image

fiogf49gjkf04

Azathioprine is effective for the maintenance of a steroid free remission in Crohn's disease.

Thiopurine methyltransferase is important for the metabolism of azathioprine and influences the production of active azathioprine metabolites.

Dr Marla Dubinsky and colleagues assessed azathioprine dose selection based on pharmacogenetic testing of thiopurine methyltransferase and metabolite monitoring.

The research team evaluated whether this treatment may offer a safety and efficacy advantage over traditional dosing strategies.

The team performed a decision analysis to estimate the potential costs and effectiveness of thiopurine methyltransferase screening.

A decision analysis was also performed to estimate the potential costs and effectiveness of metabolite monitoring.

Costly strategy with thiopurine methyltransferase was $3861 vs $7142 with community care
American Journal of Gastroenterology

The team assessed whether the decision analysis can be used as disease management strategies for Crohn's disease.

Strategies applying thiopurine methyltransferase and/or metabolite monitoring to influence treatment decisions were compared to community care.

The researchers evaluated the impact on toxicity minimization and improved time to initial and sustained response.

A 1-year model was developed from the third-party payer perspective for mild to moderately chronically active, steroid-treated Crohn's disease patients.

Effectiveness and toxicity were defined by time to response and Crohn's activity index.

The team also defined effectiveness and toxicity as time to sustained response and reduction in leukopenic events, respectively.

The researchers conducted 1- and 2-way sensitivity analyses.

The team determined the effect of varying individual estimates from those used in the base-case analysis.

Metabolite monitoring, and thiopurine methyltransferase as compared to community care achieved an earlier time to initial response.

Thiopurine methyltransferase with metabolite monitoring strategies as compared to community care achieved an earlier time to initial response.

In addition the team found that sustained response as compared to community care achieved an earlier time to initial response.

The researchers noted that least costly strategy at 1 yr was thiopurine methyltransferase at $3861.

The research team found that the most costly strategy was community care at $7142.

Each alternative strategy was shown to dominate community care by less costs and faster time to response or sustained response.

The team reported that the cost-effectiveness rankings were robust to sensitivity analyses on key variables.

The addition of alternative strategies to community care may improve azathioprine outcomes.

The researchers also found that alternative strategies reduce the total cost of care for steroid treated chronically active Crohn's patients.

Dr Dubinsky's team concluded, “Thiopurine methyltransferase was more beneficial for initial response to treatment and metabolite monitoring being more beneficial for sustained response to treatment.”

Am J Gastroenterol 2005: 100(10): 2239
07 October 2005

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us